biostudies-literatureFeldstein LRNIAID NIH HHS408-416https://www.ebi.ac.uk/biostudies/studies/S-EPMC10848053biostudies-literatureUnknown331(5)<h4>Importance</h4>Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022; however, data demonstrating the effectiveness of bivalent COVID-19 vaccines are limited.<h4>Objective</h4>To assess the effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents.<h4>Design, setting, and participants</h4>Data for the period September 4, 2022, to January 31, 2023, were combined from 3 prospective US cohort studies (6 sites total) and used to estimate COVID-19 vaccine effectiveness among children and adolescents aged 5 to 17 years. A total of 2959 participants completed periodic surveys (demographics,JAMAEffectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.PMC1084805375N93021C00015Yoon SKRuffin JGrant LHegmann KTSteinhardt LFeldstein LRNaleway ALMartin ETGaglani MRai RPMonto ASOlsho LEWBritton ABabu TMVandermeer MOdame-Bamfo LChu HYBurgess JLNewes-Adeyi GBriggs Hagen MEnglund JACaban-Martinez AJMeece JJeddy ZSmith NSaydah SWiegand RLauring ASVaughan MLutrick KMidgley CMPhillips ALEllingson KDTyner HMathenge CfalseEffectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.<h4>Importance</h4>Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022; however, data demonstrating the effectiveness of bivalent COVID-19 vaccines are limited.<h4>Objective</h4>To assess the effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents.<h4>Design, setting, and participants</h4>Data for the period September 4, 2022, to January 31, 2023, were combined from 3 prospective US cohort studies (6 sites total) and used to estimate COVID-19 vaccine effectiveness among children and adolescents aged 5 to 17 years. A total of 2959 participants completed periodic surveys (demographics,2024-01-01T00:00:00Z2024 Feb2025-04-04T03:24:43.234Z2025-04-04T03:24:43.234ZS-EPMC108480533831933110.1001/jama.2023.27022